Shift to risk-based inspection yields warnings boost; Bend formulates for BMS;

> The apparent rise in warning letters is due in part to the FDA's shift to a risk-based inspection plan, in which the goal is to select sites having the greatest process, facility and product risk associated with them, says Rick Friedman of CDER. Interview

> American Airlines plans an aggressive entry into the market for temperature-controlled pharmaceuticals to offset declines from customers who've switched to ocean freight. Article

> Bend Research will provide formulation services, some involving Bend's spray-dried dispersion technology, to Bristol-Myers Squibb for clinical trial supplies. Article

> Contract manufacturer Althea now boasts an INOVA H3-5 high-speed syringe filling line at its San Diego facility. Article

> Through a licensing agreement, Particle Sciences will offer Solumer formulation and clinical trial supply manufacturing to drug developers. Particle Sciences release

> Michelex has started moving the pharmaceutical manufacturing assets of its subsidiary, Pristine Pharma, to its own facility in New York. Michelex release

> In Viet Nam, a court imposed prison sentences totaling almost 22 years on a criminal ring of six people for producing and trading in counterfeit pharmaceuticals. Article

> Canada's Minister of Health has granted a site license to Stirling Pharma for its health products manufacturing, packaging and labeling plant in North Sydney, Nova Scotia. Item

> The Australian government and other funders are putting up $354 million to build the Translational Research Institute, a facility for the manufacture and development of drugs to treat chronic diseases. Article

> John Musante has been named VP for pharmaceutical and medical device services at supply chain specialist Tompkins Associates. Release

Suggested Articles

Fujifilm Diosynth Biotechnologies last year committed 10 billion yen toward its manufacturing operations. It has now kicked off one of those projects.

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.